Summary Epidemiological data suggest a close link between obesity and breast cancer, the most frequently occurring cancer in women. The metabolic syndrome is typically associated with abdominal obesity and comprises disturbances in glucose and/or lipid metabolism and/or hypertension. Recent studies have established a specific association between the metabolic syndrome - as well as its components - and breast cancer, indicating both an increased risk of developing breast cancer and a poorer prognosis. In premenopausal women, obesity might have a protective effect only on receptor-positive tumors, whereas a positive association was observed between obesity/abdominal obesity and an increased risk of triple-negative breast cancer (TNBC). Overall survival and disease-free survival were reported to be significantly shorter in premenopausal obese women with TNBC compared to non-obese women, but these results are still inconsistent and need further research. The metabolic syndrome is characterized by a state of insulin resistance/hyperinsulinemia and subacute chronic inflammation, with both conditions offering a plausible mechanistic link towards breast cancer. Thus, in addition to their increased risk of cardiovascular morbidity and mortality, women with this syndrome represent a group at elevated risk of developing breast cancer and with poorer prognosis.

Keywords:
Metabolic syndrome, Breast cancer, Abdominal obesity, Triple-negative breast cancer (TNBC)
1.
Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al.: Global burden of cancer. Lancet 2012;380: 1840-1850.
2.
World Cancer Research Fund/American Institute for Cancer Research: Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC, American Institute for Cancer Research (AICR), 2007.
3.
Friedenreich CM: Physical activity and breast cancer: review of the epidemiological evidence and biological mechanisms. Recent Results Cancer Res 2011;188:125-139.
4.
Protani M, Coory M, Martin JM: Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627-635.
5.
Hauner D, Janni W, Rack B, Hauner H: The effect of overweight and nutrition on prognosis of breast cancer. Dtsch Arztebl Int 2011;108:795-801.
6.
Chan DSM, Vieira AR, Aune D, et al.: Body mass index and survival in women with breast cancer - systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 2014;[Epub ahead of print], doi: 10,1093/annonc/mdn042.
7.
Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005;365:1415-1428.
8.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
9.
Alberti KGMM, Eckel RH, Grundy SM, et al.: Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
10.
Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
11.
Moebus S, Hanisch J, Bramlage P, et al.: Regional differences in the prevalence of the metabolic syndrome in primary care practices in Germany. Dtsch Arztebl Int 2008;105:207-213.
12.
Esposito K, Chiodini P, Capuano A, et al.: Metabolic syndrome and risk of postmenopausal breast cancer: a systematic review and meta-analysis. Menopause 2013;20:1301-1309.
13.
Bjørge T, Lukanova A, Jonsson H, et al.: Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010;19:1737-1745.
14.
Ewertz M, Jensen M-B, Gunnarsdottir KA, et al.: Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011;29:25-31.
15.
Ligibel JA, Strickler HD: Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions. Am Soc Clin Oncol Educ Book 2013;52-59.
16.
Yang XR, Chang-Claude J, Goode EL, et al.: Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011;103:250-263.
17.
Pierobon M, Frankenfeld CL: Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;137:307-314.
18.
Reeves KW, McLaughlin V, Fredman L, et al.: Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort. Cancer Causes Control 2012;23:1241-1251.
19.
Davis AA, Kaklamani VG: Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012;2012:809291.
20.
Vona-Davis L, Rose DP, Hazard H, et al.: Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarker Prev 2008;17:3319-3324.
21.
Turkoz FP, Solak M, Petekkaya I, et al.: The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J BUON 2013;18:335-341.
22.
Mowad R, Chu QD, Li BD, et al.: Does obesity have an effect on outcomes in triple-negative breast cancer? J Surg Res 2013;184:253s-259s.
23.
Coughlin SS, Calle EE, Teras LR, et al.: Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159:1160-1167.
24.
Peairs KS, Barone BB, Snyder CF, et al.: Diabetes mellitus and breast cancer outcomes: A systematic review and metaanalysis. J Clin Oncol 2011;29:40-46.
25.
Bodmer M, Meier C, Krayenbuhl S, et al.: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-1308.
26.
Bosco JL, Antonsen S, Sorensen HT, et al.: Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011;20:101-111.
27.
Lega IC, Austin PC, Gruneir A, et al.: Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013;36:3018-3026.
28.
Tang X, Yang L, He Z, Liu J: Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One 2013;7:e51814.
29.
Stern MP: Diabetes and cardiovascular disease: the ‘common soil' hypothesis. Diabetes 1995;44:369-374.
30.
Goodwin PJ, Ennis M, Pritchard KI, et al.: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
31.
Khandekar MJ, Cohen P, Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011;11:886-895.
32.
Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion in human adipose tissue. J Clin Endocrinol Metab 2007;92:1023-1033.
33.
Park J, Euhus DM, Scherer PE: Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev 2011;32:550-570.
34.
Nieman KM, Romero IL, Van Houten B, Lengyel E: Adipose tissue and adipocytes support tumori-genesis and metastasis. Biochim Biophys Acta 2013;1831:1533-1541.
35.
Simpson ER, Brown KA: Obesity and breast cancer: role of inflammation and aromatase. J Mol Endocrinol 2013;51:T51-T59.
36.
Byers T, Sedjo RL: Does intentional weight loss reduce cancer risk? Diabetes Obes Metab 2011; 32:550-570.
37.
Rack B, Andergassen U, Neugebauer J, et al.: The German SUCCESS C study - the first European lifestyle study on breast cancer. Breast Care 2010; 5:395-400.
38.
Rock CL, Byers T, Colditz GA, et al.: Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) trial. Contemp Clin Trials 2013;34:288-295.
39.
Cottet V, Touvier M, Fournier A, et al.: Postmenopausal breast cancer risk and dietary patterns in the E3N-EPIC prospective cohort study. Am J Epidemiol 2009;170:1257-1267.
40.
Trichopoulou A, Bamia C, Lagiou P, Trichopoulos D: Conformity to traditional Mediterranean diet and breast cancer risk in the Greek EPIC cohort. Am J Clin Nutr 2010;92:620-625.
41.
Villarini A, Pasanisi P, Traina A, et al.: Lifestyle and breast cancer recurrences: the DIANA-5 trial. Tumori 2012;98:1-18.
42.
Goodwin PJ, Pritchard KI, Ennis M, et al.: Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008; 8:501-505.
43.
Goodwin PJ, Stambolic V: Obesity and insulin resistance in breast cancer - chemoprevention strategies with a focus on metformin. Breast 2011;20 (suppl 3):S31-S35.
© 2014 S. Karger GmbH, Freiburg
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.